<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879749</url>
  </required_header>
  <id_info>
    <org_study_id>Nexvax2-001</org_study_id>
    <nct_id>NCT00879749</nct_id>
  </id_info>
  <brief_title>Safety Study of Nexvax2 in Subjects With Coeliac Disease</brief_title>
  <official_title>A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nexpep Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nexpep Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety of weekly injections of Nexvax2&#xD;
      given for three weeks to patients with coeliac disease who have been on a gluten-free diet.&#xD;
&#xD;
      The second purpose of this study is to compare the immune response over the three week study&#xD;
      period in coeliac disease patients given Nexvax2 compared to those given saline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Coeliac Disease</condition>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexvax2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9 micrograms Nexvax2</intervention_name>
    <description>9 micrograms, weekly intra-dermal injection, 3 week duration</description>
    <arm_group_label>Nexvax2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30 micrograms Nexvax2</intervention_name>
    <description>30 micrograms, weekly intra-dermal injection, 3 week duration</description>
    <arm_group_label>Nexvax2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>90 micrograms Nexvax2</intervention_name>
    <description>90 micrograms, weekly intra-dermal injection, 3 week duration</description>
    <arm_group_label>Nexvax2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>60 micrograms Nexvax2</intervention_name>
    <description>60 micrograms, weekly intra-dermal injection, 3 week duration</description>
    <arm_group_label>Nexvax2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Up to 900 micrograms Nexvax2</intervention_name>
    <description>Up to 900 micrograms, weekly intra-dermal injection, 3 week duration</description>
    <arm_group_label>Nexvax2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 microlitres 0.9% sterile sodium chloride for injection</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 60 years (inclusive)&#xD;
&#xD;
          2. Have coeliac disease meeting the following criteria:&#xD;
&#xD;
               -  the Principal Investigator is satisfied coeliac disease has been correctly&#xD;
                  diagnosed,&#xD;
&#xD;
               -  HLA DQ2 genotype (both HLA DQA1*05 and DQB1*02, homo- or hetero-zygous),&#xD;
&#xD;
               -  no known or suspected gluten exposure for 2 months prior to enrolment&#xD;
&#xD;
               -  were prescribed and have intended to follow a gluten-free diet for at least one&#xD;
                  year&#xD;
&#xD;
               -  antibodies to tissue transglutaminase (tTG) IgA and/or deamidated gliadin peptide&#xD;
                  (DGP) IgA and IgG within normal reference range at time of screening.&#xD;
&#xD;
          3. Either male or non-lactating, non-pregnant females who are postmenopausal, sterile or&#xD;
             using at least two acceptable and highly effective birth control methods.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Subjects possess the genes encoding HLA DQ8 (either DQA1*03 or DQB1*0302).&#xD;
&#xD;
          2. Uncontrolled complications of coeliac disease which, in the opinion of the&#xD;
             Investigator, would impact immune response or pose an increased risk to the subject.&#xD;
&#xD;
          3. Systemic biological agents less than 6 months prior to Day 1.&#xD;
&#xD;
          4. Receipt of systemic immunomodulatory agents or experimental drugs less than 30 days&#xD;
             prior to Day 1.&#xD;
&#xD;
          5. Any of the following laboratory abnormalities at Screening:&#xD;
&#xD;
               -  ALT, AST or alkaline phosphatase (ALP) &gt; 1.5 times the upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  Calculated creatinine clearance &lt; 80 mL/min&#xD;
&#xD;
               -  Haemoglobin (Hb) outside of the normal range&#xD;
&#xD;
               -  Platelet count &lt;125 x 109/L&#xD;
&#xD;
               -  Serum potassium outside of the normal range&#xD;
&#xD;
               -  White blood cell (WBC) count outside of the normal range&#xD;
&#xD;
               -  Thyroid stimulating hormone (TSH) outside of the normal range&#xD;
&#xD;
               -  Any other clinically significant abnormal lab values, as determined by the&#xD;
                  Clinical Investigator.&#xD;
&#xD;
          6. Subjects who smoke or who have smoked at all in the past 3 months.&#xD;
&#xD;
          7. Positive pregnancy test at Screening or Baseline.&#xD;
&#xD;
          8. History of any medically significant condition considered by the Investigator to&#xD;
             adversely affect participation in the trial.&#xD;
&#xD;
          9. Non-compliance with a gluten free diet or flare in coeliac disease symptoms from&#xD;
             Screening to Baseline.&#xD;
&#xD;
         10. Clinically relevant abnormality on ECGs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregor Brown, MBBS PhD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred Hospital, Victoria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Daveson, MBBS FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Alexandra Hospital, Queensland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm Pty Ltd</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleus Network - Centre for Clinical Studies</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>April 8, 2009</study_first_submitted>
  <study_first_submitted_qc>April 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2009</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert Anderson/Chief Executive Officer</name_title>
    <organization>Nexpep Pty Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

